Clinical stage biopharmaceutical company Carisma Therapeutics Inc on Tuesday announced an expansion of its in vivo CAR-M collaboration with Moderna Inc (Nasdaq:MRNA) to include the development of two therapies for autoimmune diseases.
Building on their successful pre-clinical work in oncology, the companies will leverage their respective technologies to develop novel in vivo macrophage engineering approaches for two nominated autoimmune disease targets.
Carisma will receive research funding and milestone payments, as well as royalties on any commercialised products.
Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024
UCB and Biogen report positive Phase 3 results for dapirolizumab pegol in SLE
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
AstraZeneca's Fasenra recommended for EU approval in EGPA
Sareum Holdings secures patent allowance for SDC-1801 in China
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Carisma and Moderna expand collaboration
Aisa Pharma receives orphan drug designation from FDA for AISA-021(cilnidipine)
Merck KGaA initiates Phase III trial for oral cladribine in gMG
ImmPACT Bio USA's IMPT-514 IND application receives US FDA approval